Articles by Thierry André, MD
Dr. André elaborates on the efficacy and safety profiles of both treatments and their influence on current therapies.
Nivolumab plus ipilimumab showed significant improvement in progression-free survival in patients in the first line setting.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.